Literature DB >> 18084608

RNA interference of interferon regulatory factor-1 gene expression in THP-1 cell line leads to Toll-like receptor-4 overexpression/activation as well as up-modulation of annexin-II.

Christos I Maratheftis1, Stavroula Giannouli, Maria P Spachidou, George Panayotou, Michael Voulgarelis.   

Abstract

Interferon regulatory factor-1 (IRF-1) is a candidate transcription factor for the regulation of the Toll-like receptor-4 (TLR-4) gene. Using a small interfering RNA-based (siRNA) process to silence IRF-1 gene expression in the leukemic monocytic cell line THP-1, we investigated whether such a modulation would alter TLR-4 expression and activation status in these cells. The siIRF-1 cells expressed elevated levels of TLR-4 mRNA and protein compared to controls by 90% and 77%, respectively. ICAM.1 protein expression and apoptosis levels were increased by 8.35- and 4.25-fold, respectively. The siIRF-1 cells overexpressed Bax mRNA compared to controls. Proteomic analysis revealed upmodulation of the Annexin-II protein in siIRF-1 THP-1 cells. Myelodysplastic syndrome (MDS) patients with an absence of full-length IRF-1 mRNA also overexpressed Annexin-II. It is plausible that this overexpression may lead to the activation of TLR-4 contributing to the increased apoptosis characterizing MDS.

Entities:  

Keywords:  Annexin II; IRF-1; RNAi; TLR-4; myelodysplastic syndrome

Mesh:

Substances:

Year:  2007        PMID: 18084608      PMCID: PMC2134898          DOI: 10.1593/neo.07640

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  43 in total

Review 1.  The interferon regulatory factors and oncogenesis.

Authors:  N Tanaka; T Taniguchi
Journal:  Semin Cancer Biol       Date:  2000-04       Impact factor: 15.707

2.  RNA interference in mammalian cells using siRNAs synthesized with T7 RNA polymerase.

Authors:  Olivier Donzé; Didier Picard
Journal:  Nucleic Acids Res       Date:  2002-05-15       Impact factor: 16.971

3.  In vivo expression of Toll-like receptor 2 and 4 by renal epithelial cells: IFN-gamma and TNF-alpha mediated up-regulation during inflammation.

Authors:  Tim G A M Wolfs; Wim A Buurman; Annemarie van Schadewijk; Bart de Vries; Marc A R C Daemen; Pieter S Hiemstra; Cornelis van 't Veer
Journal:  J Immunol       Date:  2002-02-01       Impact factor: 5.422

4.  Inhibition of lipopolysaccharide-induced apoptosis by cilostazol in human umbilical vein endothelial cells.

Authors:  Ki Young Kim; Hwa Kyoung Shin; Jae Moon Choi; Ki Whan Hong
Journal:  J Pharmacol Exp Ther       Date:  2002-02       Impact factor: 4.030

5.  The extra domain A of fibronectin activates Toll-like receptor 4.

Authors:  Y Okamura; M Watari; E S Jerud; D W Young; S T Ishizaka; J Rose; J C Chow; J F Strauss
Journal:  J Biol Chem       Date:  2001-01-09       Impact factor: 5.157

Review 6.  Activities of IRF-1.

Authors:  Andrea Kröger; Mario Köster; Katharina Schroeder; Hansjörg Hauser; Peter P Mueller
Journal:  J Interferon Cytokine Res       Date:  2002-01       Impact factor: 2.607

Review 7.  Interleukin-1/Toll receptor family members: receptor structure and signal transduction pathways.

Authors:  J M Daun; M J Fenton
Journal:  J Interferon Cytokine Res       Date:  2000-10       Impact factor: 2.607

8.  Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4.

Authors:  S T Smiley; J A King; W W Hancock
Journal:  J Immunol       Date:  2001-09-01       Impact factor: 5.422

9.  The apoptotic signaling pathway activated by Toll-like receptor-2.

Authors:  A O Aliprantis; R B Yang; D S Weiss; P Godowski; A Zychlinsky
Journal:  EMBO J       Date:  2000-07-03       Impact factor: 11.598

10.  Low expression of interferon regulatory factor-1 and identification of novel exons skipping in patients with chronic myeloid leukaemia.

Authors:  Dimitrios Tzoanopoulos; Matthaios Speletas; Konstantinos Arvanitidis; Christina Veiopoulou; Sofia Kyriaki; George Thyphronitis; Paschalis Sideras; Georgios Kartalis; Konstantinos Ritis
Journal:  Br J Haematol       Date:  2002-10       Impact factor: 6.998

View more
  7 in total

1.  Leishmania major inhibits IL-12 in macrophages by signalling through CR3 (CD11b/CD18) and down-regulation of ETS-mediated transcription.

Authors:  C Ricardo-Carter; M Favila; R E Polando; R N Cotton; K Bogard Horner; D Condon; W Ballhorn; J P Whitcomb; M Yadav; R L Geister; J S Schorey; M A McDowell
Journal:  Parasite Immunol       Date:  2013-12       Impact factor: 2.280

2.  Molecular Signature of Neuroinflammation Induced in Cytokine-Stimulated Human Cortical Spheroids.

Authors:  Kim M A De Kleijn; Kirsten R Straasheijm; Wieteke A Zuure; Gerard J M Martens
Journal:  Biomedicines       Date:  2022-04-29

3.  The War on Cancer rages on.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2009-12       Impact factor: 5.715

4.  Neoplasia: the second decade.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2008-12       Impact factor: 5.715

Review 5.  Toll-like Receptor 4, Osteoblasts and Leukemogenesis; the Lesson from Acute Myeloid Leukemia.

Authors:  Øystein Bruserud; Håkon Reikvam; Annette Katharina Brenner
Journal:  Molecules       Date:  2022-01-23       Impact factor: 4.411

6.  Annexin A2 binds to endosomes and negatively regulates TLR4-triggered inflammatory responses via the TRAM-TRIF pathway.

Authors:  Shuang Zhang; Min Yu; Qiang Guo; Rongpeng Li; Guobo Li; Shirui Tan; Xuefeng Li; Yuquan Wei; Min Wu
Journal:  Sci Rep       Date:  2015-11-03       Impact factor: 4.379

7.  GEP analysis validates high risk MDS and acute myeloid leukemia post MDS mice models and highlights novel dysregulated pathways.

Authors:  Laura Guerenne; Stéphanie Beurlet; Mohamed Said; Petra Gorombei; Carole Le Pogam; Fabien Guidez; Pierre de la Grange; Nader Omidvar; Valérie Vanneaux; Ken Mills; Ghulam J Mufti; Laure Sarda-Mantel; Maria Elena Noguera; Marika Pla; Pierre Fenaux; Rose Ann Padua; Christine Chomienne; Patricia Krief
Journal:  J Hematol Oncol       Date:  2016-01-27       Impact factor: 17.388

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.